Antigen-Specific Immunoadsorption With the Glycosorb® ABO Immunoadsorption System as a Novel Treatment Modality in Pure Red Cell Aplasia Following Major and Bidirectional ABO-Incompatible Allogeneic Hematopoietic Stem Cell Transplantation

Damodar, 2017, Donor-to-recipient ABO mismatch does not impact outcomes of allogeneic hematopoietic cell transplantation regardless of graft source, Biol Blood Marrow Transplant, 23, 795, 10.1016/j.bbmt.2017.02.009

Worel, 2016, ABO-mismatched allogeneic hematopoietic stem cell transplantation, Transfus Med Hemother, 43, 3, 10.1159/000441507

Rowley, 2011, Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation, Bone Marrow Transplant, 46, 1167, 10.1038/bmt.2011.135

Bolan, 2001, Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation, Blood, 98, 1687, 10.1182/blood.V98.6.1687

Worel, 2000, Regeneration of erythropoiesis after related- and unrelated-donor BMT or peripheral blood HPC transplantation: a major ABO mismatch means problems, Transfusion, 40, 543, 10.1046/j.1537-2995.2000.40050543.x

Helbig, 2007, Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies, Ann Hematol, 86, 677, 10.1007/s00277-007-0304-8

Rabitsch, 2003, Prolonged red cell aplasia after major ABO-incompatible allogeneic hematopoietic stem cell transplantation: removal of persisting isohemagglutinins with Ig-Therasorb immunoadsorption, Bone Marrow Transplant, 32, 1015, 10.1038/sj.bmt.1704264

Rabitsch, 2003, Removal of persisting isohaemagglutinins with Ig-Therasorb immunoadsorption after major ABO-incompatible non-myeloablative allogeneic haematopoietic stem cell transplantation, Nephrol Dial Transplant, 18, 2405, 10.1093/ndt/gfg364

Shahan, 2015, Successful treatment of refractory pure red cell aplasia with bortezomib after allogeneic haematopoietic cell transplantation in a patient with alpha-beta subcutaneous panniculitis-like T celllymphoma, Transfus Med, 25, 342, 10.1111/tme.12216

Chapuy, 2018, Daratumumab for delayed red-cell engraftment after allogeneic transplantation, N Engl J Med, 379, 1846, 10.1056/NEJMoa1807438

Zhidong, 2012, Successful treatment of pure red cell aplasia with a single low dose of rituximab in two patients after major ABO incompatible peripheral blood allogeneic stem cell transplantation, Transfus Med, 22, 302, 10.1111/j.1365-3148.2012.01156.x

Deotare, 2006, Response to high-dose dexamethasone for acquired pure red cell aplasia following ABO-mismatched allogeneic stem cell transplantation, Bone Marrow Transplant, 37, 1149, 10.1038/sj.bmt.1705378

Schiesser, 2015, The reuse of immunoadsorption columns in ABO-incompatible kidney transplantation is efficient: the swiss experience, Transplantation, 99, 1030, 10.1097/TP.0000000000000457

Kumlien, 2006, Clinical experience with a new apheresis filter that specifically depletes ABO blood group antibodies, Transfusion, 46, 1568, 10.1111/j.1537-2995.2006.00927.x

Penack, 2020, Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation, Lancet Haematol, 7, e157, 10.1016/S2352-3026(19)30256-X

Worel, 2007, Prophylactic red blood cell exchange for prevention of severe immune hemolysis in minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation after reduced-intensity conditioning, Transfusion, 47, 1494, 10.1111/j.1537-2995.2007.01289.x

Wahrmann, 2012, Anti-A/B antibody depletion by semiselective versus ABO blood group-specific immunoadsorption, Nephrol Dial Transplant, 27, 2122, 10.1093/ndt/gfr610

Aung, 2013, Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation, Br J Haematol, 160, 798, 10.1111/bjh.12210

Yamaguchi, 2002, Treatment of pure red cell aplasia after major ABO-incompatible peripheral blood stem cell transplantation by induction of chronic graft-versus-host disease, Bone Marrow Transplant, 30, 539, 10.1038/sj.bmt.1703699

El-Jawahri, 2016, Improved treatment-related mortality and overall survival of patients with grade IV acute GVHD in the modern years, Biol Blood Marrow Transplant, 22, 910, 10.1016/j.bbmt.2015.12.024

Nixon, 2017, Infectious complications of rituximab therapy in renal disease, Clin Kidney J, 10, 455, 10.1093/ckj/sfx038

Griffith, 2005, Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation, Br J Haematol, 128, 668, 10.1111/j.1365-2141.2005.05364.x

Hirokawa, 2013, Efficacy and long-term outcome of treatment for pure red cell aplasia after allogeneic stem cell transplantation from major ABO-incompatible donors, Biol Blood Marrow Transplant, 19, 1026, 10.1016/j.bbmt.2013.04.004

Mikulska, 2012, Mortality after bloodstream infections in allogeneic haematopoietic stem cell transplant (HSCT) recipients, Infection, 40, 271, 10.1007/s15010-011-0229-y

Thölking, 2015, Antigen-specific versus non-antigen-specific immunoadsorption in ABO-incompatible renal transplantation, PLoS ONE, 10, e0131465, 10.1371/journal.pone.0131465

Zöllner, 2014, Fibrinogen reduction and bleeding complications in plasma exchange, immunoadsorption and a combination of the two, Blood Purif, 38, 160, 10.1159/000367682

Aung, 2016, Pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplantation is associated with severe pancytopenia, Biol Blood Marrow Transplant, 22, 961, 10.1016/j.bbmt.2016.02.008

Wilpert, 2007, ABO-incompatible kidney transplantation-proposal of an intensified apheresis strategy for patients with high initial isoagglutinine titers, J Clin Apher, 22, 314, 10.1002/jca.20153

Biesenbach, 2014, Long-term outcome of anti-glomerular basement membrane antibody disease treated with immunoadsorption, PLoS ONE, 31, e103568, 10.1371/journal.pone.0103568

Kim, 2014, Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options, Pharmacotherapy, 34, 733, 10.1002/phar.1426